Balancing Cost, Innovation, and Access: A Comparative Institutional Analysis of Pharmaceutical Pricing Tools in High-Income Health Systems
Bibliographic record
Abstract
Background: Soaring drug prices threaten affordability and equity in high-income health systems. This study examines how two families of reform tools, international reference pricing (including the U.S. Most Favored Nation–type proposals and Canada’s PMPRB comparators) and value-based payment approaches, perform across four core policy goals: cost containment, innovation, equity, and implementation feasibility.Methods: Guided by institutional and governance theories, we conducted a structured comparative policy analysis of the United States, Canada, and the United Kingdom using a four-dimensional trade-off matrix. We coded 37 documents (2007–2025), including policy guidance, legislation, and empirical evaluations, to rate each country–instrument pair (1–5) on cost, innovation incentives, equity of access, and feasibility, based on design features rather than realized outcomes.Results: The U.K.’s integrated model, combining NICE’s cost-effectiveness appraisals with the voluntary scheme for branded medicines (VPAG), shows the most consistent alignment across all four dimensions. Canada’s PMPRB-based system achieves strong cost control and broad baseline access but provides weaker, indirect innovation incentives and limited outcome-linked pricing. In the U.S., MFN-type proposals and pharmaceutical value-based contracts face legal challenges, fragmented payers, and limited infrastructure, resulting in low scores on equity and feasibility despite some innovation-supportive features.Conclusions: Neither international reference pricing nor value-based payment alone is sufficient to advance Universal Health Coverage goals. A hybrid approach, anchoring negotiations in international benchmarks while linking reimbursement to therapeutic value, appears more realistic for fragmented systems such as the U.S., but only if accompanied by investments in data, governance, and federal negotiating capacity. The trade-off matrix offers a repeatable framework for assessing pricing reforms and illustrates how institutional “fit,” rather than technical design alone, shapes policy success.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.023 | 0.063 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.009 | 0.009 |
| Science and technology studies | 0.003 | 0.007 |
| Scholarly communication | 0.005 | 0.005 |
| Open science | 0.002 | 0.005 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".